

24 July 2024

**Aptamer Group plc**

**("Aptamer", the "Company" or the "Group")**

**Posting of Circular and Notice of General Meeting**

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces further to the announcement made earlier today relating to its proposed Firm Placing, Conditional Placing and Subscription to raise approximately £2.83 million ("Announcement"), that it has despatched the Circular and Notice of General Meeting to Shareholders.

The Directors confirm they are to convene a General Meeting of the Company at 11:00 a.m. on Tuesday 13 August 2024 at Windmill House, Innovation Way, York, YO10 5BR.

The Circular and Notice of General Meeting is available on the Company's website at <https://aptamergroup.com/investors/reports-and-presentations/>

The results of voting on all resolutions at the General Meeting will be announced via a Regulatory News Service and the full results of the voting will be published on the Company's website, as soon as practicable after the conclusion of the General Meeting.

*Capitalised terms used but not otherwise defined in this announcement shall have the meanings ascribed to such terms in the Announcement, unless the context requires otherwise.*

**- ENDS -**

For further information, please contact:

**Aptamer Group plc** +44 (0) 1904 217 404  
Dr Arron Tolley

**SPARK Advisory Partners Limited - Nominated Adviser** +44 (0) 20 3368 3550  
Andrew Emmott / Adam Dawes

**Turner Pope Investments (TPI) Limited - Broker** +44 (0) 20 3657 0050  
James Pope / Andrew Thacker

**About Aptamer Group plc**

[Aptamer](#) Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer® platform.

Optimer® binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over \$170 billion. Optimer® binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer® technology and processes, scientists and collaborators can make faster, more informed decisions that speed discovery and development across the life sciences.

more informed decisions that support discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOGBRGDRGBDDGSS